Hua Tian, Vemuri Kiran, Pu Mengchen, Qu Lu, Han Gye Won, Wu Yiran, Zhao Suwen, Shui Wenqing, Li Shanshan, Korde Anisha, Laprairie Robert B, Stahl Edward L, Ho Jo-Hao, Zvonok Nikolai, Zhou Han, Kufareva Irina, Wu Beili, Zhao Qiang, Hanson Michael A, Bohn Laura M, Makriyannis Alexandros, Stevens Raymond C, Liu Zhi-Jie
iHuman Institute, ShanghaiTech University, Shanghai 201210, China; National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Center for Drug Discovery, Department of Pharmaceutical Sciences and Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA 02115, USA.
Cell. 2016 Oct 20;167(3):750-762.e14. doi: 10.1016/j.cell.2016.10.004.
Cannabinoid receptor 1 (CB) is the principal target of Δ-tetrahydrocannabinol (THC), a psychoactive chemical from Cannabis sativa with a wide range of therapeutic applications and a long history of recreational use. CB is activated by endocannabinoids and is a promising therapeutic target for pain management, inflammation, obesity, and substance abuse disorders. Here, we present the 2.8 Å crystal structure of human CB in complex with AM6538, a stabilizing antagonist, synthesized and characterized for this structural study. The structure of the CB-AM6538 complex reveals key features of the receptor and critical interactions for antagonist binding. In combination with functional studies and molecular modeling, the structure provides insight into the binding mode of naturally occurring CB ligands, such as THC, and synthetic cannabinoids. This enhances our understanding of the molecular basis for the physiological functions of CB and provides new opportunities for the design of next-generation CB-targeting pharmaceuticals.
大麻素受体1(CB1)是Δ-四氢大麻酚(THC)的主要靶点,THC是一种来自大麻的精神活性化学物质,具有广泛的治疗应用,且有着悠久的娱乐使用历史。CB1由内源性大麻素激活,是疼痛管理、炎症、肥胖和药物滥用障碍的一个有前景的治疗靶点。在此,我们展示了与AM6538(一种为该结构研究而合成和表征的稳定拮抗剂)结合的人源CB1的2.8埃晶体结构。CB1-AM6538复合物的结构揭示了该受体的关键特征以及拮抗剂结合的关键相互作用。结合功能研究和分子建模,该结构为天然存在的CB1配体(如THC)和合成大麻素的结合模式提供了深入了解。这增强了我们对CB1生理功能分子基础的理解,并为下一代靶向CB1的药物设计提供了新机会。